Home

Chronic obstructive pulmonary disease PDF

(PDF) Chronic Obstructive Pulmonary Disease (COPD

Chronic Obstructive Pulmonary Disease (COPD) ICSI has endorsed with qualifications the Veteran's Affairs/Department of Defense (VA/DoD) Clinical Practice Guideline for the Management of Chronic Obstructive Pulmonary Disease. Using the ICSI endorsement process, this document has been reviewed by the ICSI COPD work group: Anderson B patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respir Res. 2013 Nov 14;14:125. PMID: 24229360. Blasi F, Bonardi D, Aliberti S, et al. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm Pharmacol Ther. 2010 Jun;23(3):200-7. PMID: 2002598 The focus of this guideline is on medical nutrition therapy (MNT) for people with chronic obstructive pulmonary disease (COPD). COPD is a leading cause of death in both the United States and world-wide. 1, 2 COPD is described by the American Thoracic Society as a slowly progressive lung disease that is characterized b Almost 16 million Americans have been diagnosed with chronic obstructive pulmonary disease (COPD). The actual prevalence is likely much higher since many people with low pulmonary function are not aware of their condition and remain undiagnosed.1,2,3 COPD was the 4th leading cause of death in the United States in 2017 and the 2 nd mos

Chronic obstructive pulmonary disease in adults (PDF

  1. When the Global Initiative for Chronic structiveOb Lung Disease (GOLD) program was initiated in 1998, a goal was to produce recommendations for management of COPD based on the best scientific information available. The first report
  2. CHRONIC OBSTRUCTIVE PULMONARY DISEASE By: Eva Jacobson, Legislative Fellow ISSUE This report answers a series of questions on Chronic Obstructive Pulmonary Disease (COPD) that address (1) screening and diagnostic methods, (2) its prevalence and associated health care costs in Connecticut, and (3) local and national advocacy organizations. 1
  3. See Chronic obstructive pulmonary disease / Diagnosing and assessing COPD . 4 . Managing COPD . See Chronic obstructive pulmonary disease / Managing COPD . 5 . Managing coexisting conditions . NICE has produced a visual summary on non-pharmacological management and use of inhaled therapies for COPD. Alpha-1 antitrypsin deficienc
  4. Chronic obstructive pulmonary disease (COPD) is a progressive lung disease caused by chronic smoke inhalation and characterized by persistent airflow obstruction to the lungs that is not fully.

Chronic obstructive pulmonary disease (COPD) is a slowly progressive condition characterized by airflow limitation, which is largely irreversible . Cigarette smoking is the main etiologic factor in this condition, far outweighing any of the other risk factors Chronic obstructive pulmonary disease (COPD) COPD describes a group of lung conditions that make it difficult to empty air out of the lungs because the airways have become narrowed. This information covers what COPD is, the symptoms you might get, and how it's diagnosed and treated

Chronic obstructive pulmonary disease (COPD), the fourth leading cause of death in the United States, is a major public health problem that is both preventable and treatable. COPD is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways an Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease that is preventable and treatable. COPD is characterized by long-term respiratory symptoms and airflow limitation. The main symptoms include shortness of breath and a cough which may or may not produce mucus. COPD progressively worsens with everyday activities such as walking or dressing becoming difficult

Chronic obstructive pulmonary disease (COPD) is a progressive disease state characterized by airflow limitation that is not fully reversible. Suspected in patients with a history of smoking, occupational and environmental risk factors, or a personal or family history of chronic lung disease. Pres.. Chronic obstructive pulmonary disease. Macrophages, neutrophils, eosinophils, and dendritic cells, recruited to the site of inflammation, constitute the innate immune response. Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease

between chronic obstructive pulmonary disease and various types of physical and chemical exposures at work. . Retrieved 11 November 2013, from http://www.ask.dk/~/media/ASK/pdf/vejledninger/occupational%20copdkolpdf.a shx 70002 . Abramson M, Glasgow N, McDonald C (2007). Managing chronic obstructive pulmonary disease. Australian Prescriber, 30(3): 64-7 Chronic Obstructive Pulmonary Disease Association, Singapore . Tel: (65) 6325 9220 Fax: (65) 6224 1677 www.moh.gov.sg Chronic. Correlation of Medication Therapy in Chronic Obstructive Pulmonary Disease(COPD) Patients with 30-day Readmission Rates PPT Version | PDF Version; Djebbar Atmani Effect of Fraxinus angustifolia (Oleacea) leaf and bark extracts on acute and chronic inflammation: enhanced activity of nanovesicle-trapped extracts PPT Version | PDF Version; Maria O. Longa chronic obstructive pulmonary disease (copd) - suspected april 2018 page 7 of 15 This map was published by MidCentral District. A printed version of this document is not controlled so may not be up-to-date with the latest clinical information Background. Chronic obstructive pulmonary disease (COPD) patients have multiple comorbidities which may affect renal function. Chronic kidney disease (CKD) is a risk factor for adverse outcomes in.

Ahmadi et al. Respiratory Research (2020) 21:216 Page 2 of 11 Background Moreover, high oxidative stress in COPD might cause Chronic obstructive pulmonary disease (COPD) is a re- more muscle degeneration and worsen other symptoms. spiratory disorder characterized by progressive airflow Inflammatory mediators' expression by reactive oxygen. • an acute exacerbation of chronic obstructive pulmonary disease (COPD) is a sustained worsening of symptoms from a person's stable state • a range of factors (including viral infections and smoking) can trigger an exacerbatio The disease processes associated with COPD are: • Chronic bronchitis - daily sputum production for at least three months, of two or more consecutive years • Emphysema - alveolar dilation and destruction • Chronic asthma There is significant overlap in the disease processes associated with COPD The COPDX Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2003 By Nicholas Glasgow , David McKenzie , and Michael Abramson Diagnosis and Management of Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline from the American College of Physician Chronic Obstructive Pulmonary Disease (COPD) is an umbrella term for a group of conditions that cause obstruction of airflow in the breathing tubes or airways of the lungs. These conditions commonly include chronic bronchitis, emphysema and chronic asthma. When the condition occurs it is chronic (long term

Download Free PDF. Download Free PDF. Chronic obstructive pulmonary disease. Lancet, 2003. PauL WalkeR. Download PDF. Download Full PDF Package. This paper. A short summary of this paper. 37 Full PDFs related to this paper. AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE UPDATED 2015. By 111 111 Chronic Obstructive Pulmonary Disease An Issue of Clinics in Chest Medicine E Book Book Description: This issue of Clinics in Chest Medicine, guest-edited by Dr. Gerard Criner and Dr. Bartolome Celli, is focused on Chronic Obstructive Pulmonary Disease

Introduction. Chronic obstructive pulmonary disease (COPD) is the leading cause of death for both males and females in the United States and is projected to rise in ranking by 20201.According to data from the National Center for Health Statistics of the Centers for Disease Control and Prevention, COPD became the third leading cause of death by 20082 The goal of this study was to gain an understanding of participants' experiences with chronic obstructive pulmonary disease (COPD) and their perceptions of an occupational therapy intervention as it related to occupational behaviors. The researcher conducted semistructured interviews with three participants recruited from a pulmonary rehabilitation program in Hong Kong Key words: chronic obstructive pulmonary disease, endurance, exercise, pulmonary rehabilitation, skeletal muscle, strength. INTRODUCTION Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity, mortality, and health care use [1]. Exercise intolerance is one of the most troubling manifestations of COPD. Persons with mild.

Chronic Obstructive Pulmonary Disease Request PD

4. Blanc P, Toren K (2007). Occupation in chronic obstructive pulmonary disease and chronic bronchitis: an update. Int J Tuberc Lung Dis 11(3):251-257 5. American Thoracic Society (2003). American Thoracic Society Statement: Occupational contribution to the burden of airway disease. Am J Respir Crit Care Med 167:787-797 6 Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019 [1]. Over 80% of these deaths occurred in low- and middle-income countries (LMIC). COPD causes persistent and progressive respiratory symptoms, including difficulty in breathing, cough and/or phlegm production

Pathogenesis of Chronic Obstructive Pulmonary Diseas

  1. chronic obstructive pulmonary disease Control approach 4 Special COSHH essentials: General guidance G440011 Introduction Your work involves dust, fume or an irritating substance that could cause the lung disease chronic obstructive pulmonary disease (COPD). This includes chronic bronchitis and emphysema
  2. Chronic obstructive pulmonary disease (COPD) is characterized by progressive and largely irreversible airflow limitation due to narrowing and fibrosis of small airways and loss of airway alveolar attachments as a result of emphysema. Cigarette smoking is the most important risk factor, but other noxious gases are important in developing countries
  3. There are 1.3 million people in the UK with a diagnosis of chronic obstructive pulmonary disease (COPD) and the condition is responsible for considerable morbidity and mortality.1 COPD is also a common cause of hospital admission. NHS England has now recognised respiratory disease as a priority area in the Long Term Plan,2 but Royal College of Physicians COPD Audits3 identify substantial.
  4. Chronic Obstructive Pulmonary Disease Program Implementation Guide Introduction The Society of Hospital Medicine (SHM) is pleased to make this Implementation Guide available as a tool to help you to improve the care of patients who are hospitalized for an exacerbation of chronic obstructive pulmonary disease (COPD)

Chronic obstructive pulmonary disease (COPD) is a common disease with high global morbidity and mortality. COPD is characterized by poorly reversible airway obstruction, which is confirmed by spirometry, and includes obstruction of the small airways (chronic obstructive bronchiolitis) and emphysema, which lead to air trapping and shortness of breath in response to physical exertion Chronic obstructive pulmonary disease (COPD) is a growing problem worldwide and a major cause of disability, hospital admission and premature death (Pauwels and Rabe, 2004). It is projected to become the third most common cause of death by the year 2020 (Murray and Lopez, 1996). From the patient's perspective, it is also a disease that has a.

Volume 8, Issue 3 - 2021. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation is an open access, peer-reviewed medical/scientific journal dedicated to publishing original research, reviews, and communications related to COPD. Articles are published online as quickly as possible following peer review and editorial acceptance and then aggregated into quarterly issues, and made. hronic obstructive pulmonary disease (COPD) is a slowly progressive disease involving the airways or pul-monary parenchyma (or both) that results in airflow ob-struction. Manifestations of COPD range from dyspnea, poor exercise tolerance, chronic cough with or without sputum production, and wheezing to respiratory failure or cor pulmonale diseases in which the airways narrow, making it difficult to expel air from the lungs. In patients with chronic obstructive pulmonary disease, exacerbations are significant events in the illness process (COPD). They have a negative impact on the patient's quality of life as well as the disease's progression

Chronic Obstructive Pulmonary Disease (COPD) remains a major public health problem. It is the fourth leading cause of chronic morbidity and mortality in the United States, and is projected to rank fifth in 2020 in burden of disease caused worldwide, according to a study published by the World Bank/World Health Organization COPD(CHRONIC OBSTRUCTIVE PULMONARY DESEASE) COPD is the co occurrence of chronic bronchitis and emphysema, a pair of commonly coexisting disease in which the airways become narrow. COPD is the preventable and treatable lung disease with some significant pulmonary and systematic features. 6. PULMONARY AND SYSTEMATIC FEATURES OF COPD 7 The Global Initiative for Obstructive Lung Disease defines Chronic Obstructive Pulmonary Disease, COPD, as follows: COPD is a preventable and treatable disease with some signif-icant extrapulmonary effects that may contribute to the severity in individual patients. Its pulmonary component is characterize

Chronic obstructive pulmonary disease - Wikipedi

Chronic obstructive pulmonary disease (COPD) is a systemic inflammatory condition associated with several comorbidities, including lung cancer. It is a major cause of global morbidity and mortality, with 328 million people affected worldwide and 3.5-4 million deaths annually Chronic obstructive pulmonary disease (COPD) kills more than 3 million people worldwide every year. Despite progress in the treatment of symptoms and prevention of acute exacerbations, few advances have been made to ameliorate disease progression or affect mortality

Chronic obstructive pulmonary disease (COPD) - Guidelines

Chronic obstructive pulmonary disease (COPD/emphysema) is a life-threatening disorder with high morbidity and mortality that is prevalent worldwide. It is characterized by destruction of the alveolar wall and a decline in lung function. However, few palliative therapies are currently available. We show that FCH and double SH3 domains 1 ( Fchsd1 ) knockout mice are protected against airspace. View as PDF Send by post Chronic obstructive pulmonary disease (COPD) is a lung disease in which the lung is damaged, making it hard to breathe. In COPD, the airways - the tubes that carry air in and out of your lungs - are partly obstructed, making it difficult to get air in and out Chronic obstructive pulmonary disease (COPD) is a preventable and treatable lung disease characterised by chronic obstruction of lung airflow that interferes with normal breathing and is not fully reversible. The symptoms of COPD include cough, sputum production, and dyspnoea (difficult or labored breathing) Chronic obstructive. pulmonary disease. Characterized by an airflow limitation in the respiratory airways, chronic obstructive pulmonary disease (COPD) is the result of chronic bronchial inflammation. The main symptom of COPD is breathlessness, which becomes more pronounced over time, contributing to a further respiratory handicap

Chronic obstructive pulmonary disease - The Lance

Chronic Obstructive Pulmonary Disease (Acute and Postacute) Health Quality Ontario & Ministry of Health and Long-Term Care February 2015 (This handbook includes, in its acute phase, an update of the Clinical Handbook for Chronic Obstructive Pulmonary Disease, published in April 2013. Nursing Care of Dyspnea: The 6th Vital Sign in Individuals with Chronic Obstructive Pulmonary Disease (COPD) 2 Development Panel Members Declarations of interest and confidentiality were made by all members of the guideline development panel. Further details are available from the Registered Nurses' Association of Ontario Chronic Obstructive Pulmonary Disease (COPD) Market is expected to register a CAGR of 4.7% to touch USD 25.7 Billion from 2019 to 2025. Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Its symptoms include breathing difficulty, cough, mucus production and wheezing

Chronic Obstructive Pulmonary Disease Mexico PDF PPT

  1. INTRODUCTION. Chronic obstructive pulmonary disease (COPD) is a common respiratory condition characterized by airflow limitation [].It affects more than 5 percent of the population and is associated with high morbidity and mortality [].It is the fourth-ranked cause of death in the United States, killing more than 120,000 individuals each year []..
  2. COPD Guidelines: The COPD-X plan Version 2.63, February 2021 Lung Foundation Australia's COPD Guidelines Committee, manages the co-branded Lung Foundation and Thoracic Society of Australia and New Zealand's, The COPD-X Plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease. To ensure you stay up-to-date with these guidelines, register.
  3. Background: Chronic obstructive pulmonary disease (COPD) is characterized by an incompletely reversible limitation in airflow. A physiological variable--the forced expiratory volume in one second (FEV1)--is often used to grade the severity of COPD. However, patients with COPD have systemic manifestations that are not reflected by the FEV1
  4. Chronic obstructive pulmonary disease (COPD) is a common disease with high global morbidity and mortality. COPD is characterized by poorly reversible airway obstruction, which is confirmed by.
  5. Chronic Obstructive Pulmonary Disease (COPD) represents an important public health challenge and is a major cause of chronic morbidity and mortality throughout the world. COPD is currently the fourth leading cause of death in the world. 1. but is projected to be the 3. rd
  6. Introduction. People who suffer from stigmatized chronic health conditions 1 are often devalued and, as a result, are less likely to access and obtain medical care for their symptoms 2 and more likely to experience delays in diagnosis. 1 Due to its link to smoking, chronic obstructive pulmonary disease (COPD) is one of these stigmatized chronic conditions. 3,4 Because most people who develop.
  7. Chronic Obstructive Pulmonary Disease (COPD) is estimated to affect 15% of all New Zealanders aged over 45 years. It is the fourth leading cause of death in New Zealand behind cancer, heart disease and stroke. COPD is permanent, disabling and frequently progressive. Over 85% of cases of COPD are caused by inhalation of tobacco smoke
CDC - For Clinicians - Chronic Obstructive Pulmonary

(PDF) Predictors of Renal Function Worsening in Patients

COPD: Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease (COPD) can significantly affect one in four adults, and a COPD exacerbation can be a very common complaint for EMS providers. COPD includes several different disease processes in the definition MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE QUICK REFERENCE FOR HEALTH CARE PROVIDERS Diagnosis and Assessment of COPD A diagnosis of COPD should be considered in any individual with symptoms of chronic cough, sputum production or dyspnoea and a history of exposure to risk factors for the disease, especially cigarette smoking COPD is an acronym for Chronic Obstructive Pulmonary Disease. It is generally applied to patients who show persistent airway obstruction and decreased expiratory flow rates. Approximately 14-16 million people in the u.s. Are currently diagnosed with COPD Asthma (Chronic Obstructive Pulmonary Disease) The Swas Clinic is a clinic run by the Family Health Center for people with conditions such as asthma ,Chronic obstructive pulmonary disease. Identification of a probable case of COPD/Asthma based on clinical features and staging of illness by spirometry as per SWAAS guidelines

(PDF) Fortified whey beverage for improving muscle mass in

Chronic Obstructive Pulmonary Disease Clinical features Exertional dyspnoea Chronic cough with regular sputum production Wheeze Investigations Spirometry o Obstructive pattern: ↓FEV 1 (<80%), normal FVC (>80%), ↓FEV 1 /FVC ratio (<0.7) o FEV 1 grades severity Chest X-ray o Hyperinflation (>8 anterior ribs visible) o Flat hemi-diaphragm Chronic obstructive pulmonary disease (COPD) Page 7 assessment tool. NICE updated their guidelines in December 2019, and so these have now been broadly adopted. There is an easy to follow flowchart that NICE have produced, Chronic obstructive pulmonary disease in over 16s: non-pharmacological management and use of inhaled therapies Evolving therapies in chronic obstructive pulmonary disease 11 3 2014 Practice points • An estimated three million people die of chronic obstructive pulmonary disease (COPD) every year, and the prevalence of COPD is increasing. By 2020, COPD is expected to become the third-leading cause of death worldwide Chronic obstructive pulmonary disease This guideline does not apply to people with COPD and asthma overlap. [1] Increased risk of pneumonia with inhaled corticosteroid use Check inhaler technique at every opportunity Inhaler device is more important than drug choice. Please try to consider device continuity when prescribing different inhalers

Media Kit for Global Initiative Chronic Obstructive Lung

Chronic obstructive pulmonary disease (acute exacerbation

  1. Chronic Obstructive Pulmonary Disease. Patient population: Objectives: 1. Provide a framework for management of chronic COPD and for the treatment of mild to moderate acute exacerbations. 2. Improve symptoms, quality of life and lung function while reducing morbidity and mortality for
  2. The rate of chronic obstructive pulmonary disease hospitalisations in Canterbury DHB was significantly lower than the national rate, although Māori had a significantly higher rate than all other ethnic groups, both locally and nationally (see Table 2, below)
  3. sessions, followed by rest periods between sessions. When patient tolerates 20
  4. Chronic Obstructive Pulmonary Disease (COPD) and asthma to deliver on the Coalition Government's commitment to improve health outcomes and reduce inequalities. 'An Outcomes Strategy for COPD and Asthma' is accompanied by the following documents, published individually: An Outcomes Strategy fo
  5. Chronic obstructive pulmonary disease (COPD) is characterised by an inappropriate/excessive inflammatory response of the lungs to respiratory pollutants, mainly tobacco smoking. Recently, besides the typical pulmonary pathology of COPD ( i.e. chronic bronchitis and emphysema), several effects occurring outside the lungs have been described, the so-called systemic effects of COPD

(PDF) Chronic obstructive pulmonary disease PauL WalkeR

-PDF- Chronic Obstructive Pulmonary Disease An Issue Of

See corresponding editorial on page 1301.. INTRODUCTION. Malnutrition is a common problem in individuals with chronic obstructive pulmonary disease (COPD) 4 with prevalence rates in inpatients of between 30% and 60% and in outpatients of between 10% and 45% ().Malnourished COPD patients have greater gas trapping, lower diffusing capacity, and a lower exercise capacity when compared with. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176 (6):532-555. • Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) is a major and increasing global health problem that is now a leading cause of death. COPD is associated with a chronic inflammatory response, predominantly in small airways and lung parenchyma, which is characterized by increased numbers of macrophages, neutrophils, and T lymphocytes. The inflammatory mediators involved in COPD have not been.

Pneumonia in Patients with Chronic Obstructive Pulmonary

  1. Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality throughout the world and the incidence will continue to rise especially in the developing countries as the prevalence of smoking increases. By 2020 COPD is expected to be the 3rd commonest cause o
  2. Chronic obstructive pulmonary disease is a long-term condition of the lungs where the flow of air to the lungs is restricted (obstructed). Symptoms include cough and breathlessness. The condition is most often caused by smoking and the most important treatment is to stop smoking. Inhalers are commonly used to ease symptoms
  3. Introduction. Acute exacerbations, punctuating the natural history of chronic obstructive pulmonary disease (COPD), are associated with significant mortality as well as health and socioeconomic burden.1-3 They are the main drivers of the poor outcomes of COPD, which is consequently ranked as a leading cause of death and disability globally.1-3 It is estimated that every year 22%-40% of.

[PDF] Chronic obstructive pulmonary disease and engagement

Chronic obstructive pulmonary disease (COPD) is a lung disease characterised by persistent respiratory symptoms and airflow obstruction. COPD is a triad of emphysema, chronic bronchitis and small airway fibrosis. Chronic bronchitis is defined as a productive cough for at least 3 months in 2 consecutive years. 1 In the UK, the prevalence of COPD. COPD (chronic obstructive pulmonary disease) is a group of lung diseases that make it hard to breathe and get worse over time. Normally, the airways and air sacs in your lungs are elastic or stretchy. When you breathe in, the airways bring air to the air sacs. The air sacs fill up with air, like a small balloon The product is a PDF. The publisher has been monitoring the chronic obstructive pulmonary disease drugs market and it is poised to grow by $ 5.63 bn during 2021-2025, progressing at a CAGR of 5.68% during the forecast period. The report on the chronic obstructive pulmonary disease drugs market provides a holistic analysis, market size and. Key words: breathing exercises, chronic obstructive pulmo-nary disease (COPD), controlled breathing, dyspnea, inspira-tory muscle training, physiotherapy. INTRODUCTION Dyspnea is an important and debilitating symptom in patients with chronic obstructive pulmonary disease (COPD) [1]. Some pathophysiological factors known t

Chronic obstructive pulmonary disease (COPD

In 1981, Woodcock and colleagues1 published the first clinical study of opioids for the management of breathlessness in severe chronic obstructive pulmonary disease (COPD). They found that dihydrocodeine offered a short-term benefit but cautioned readers that the risks of respiratory depression and.. INTRODUCTION. Chronic obstructive pulmonary disease (COPD) is a common condition with an estimated global prevalence of almost 12 percent in adults over age 30 [].COPD is the fourth leading cause of death among adults worldwide and is expected to become the third leading cause of death by 2020 [].In the majority of patients with COPD, symptoms and exacerbations can be controlled with.

Chronic obstructive pulmonary disease (COPD) - Etiology

Prevention of COPD Exacerbations | Journal of the COPDTuberculosis: classification, morphology, clinicalDoes This Patient Have Clubbing? | Chronic ObstructiveAsthma/EID | NATA